What is HCG?
Human chorionic gonadotropin (HCG) is a glycoprotein hormone naturally produced by the syncytiotrophoblast cells of the placenta during pregnancy. It is the hormone detected by pregnancy tests from the earliest weeks of gestation, and its primary physiological role is to maintain the ovarian corpus luteum during the first trimester — ensuring progesterone production that sustains the pregnancy until the placenta takes over that function.
However, HCG has an entirely different application in the context of research on the male reproductive axis and hormone replacement therapy (TRT). Its molecular structure shares very high homology with pituitary LH (luteinizing hormone), allowing it to bind and activate the same LH/hCG receptors on testicular Leydig cells, thereby stimulating intragonadal testosterone synthesis.
This property makes HCG a uniquely useful research tool: it acts directly on the testis without going through the hypothalamic-pituitary axis, allowing testicular function to be maintained even when that axis is suppressed by exogenous testosterone use.
Mechanism of Action
HCG binds with high affinity to the LHCGR receptor (LH/chorionic gonadotropin receptor) present primarily in:
-
Leydig cells (testis): Activates the cAMP → PKA → StAR (steroidogenic acute regulatory protein) pathway, initiating the conversion of cholesterol to testosterone. Also stimulates local production of intratesticular IGF-1, which amplifies the steroidogenic effect.
-
Granulosa cells and corpus luteum (ovary): Stimulates progesterone and estrogen production, and can be used to trigger ovulation as an alternative to the endogenous LH surge.
-
Sertoli cells (testis): Indirectly, elevated intratesticular testosterone stimulates spermatogenesis and maintenance of the germinal epithelium.
Reported Research Protocols
TRT Support (Testicular Maintenance)
Exogenous testosterone use suppresses pituitary LH and FSH secretion (negative feedback), leading to progressive testicular atrophy and suppression of spermatogenesis. HCG administered concurrently acts as an LH surrogate, maintaining testicular volume and intratesticular testosterone production.
Typical protocol: 500 IU SC, twice per week. Administered on days opposite to testosterone injections when possible.
Male Fertility
In hypogonadotropic hypogonadism (central LH/FSH deficiency), HCG combined with FSH or HMG can restore spermatogenesis.
Protocol: 1000-2000 IU SC, three times per week, over extended cycles (3-6 months or more).
Post-Cycle Restoration (PCT)
After cycles involving androgenic compounds, the HPG axis (hypothalamus-pituitary-gonads) may take weeks or months to recover. HCG directly stimulates Leydig cells during this recovery period.
PCT protocol: 500-1000 IU/day for 10 days, followed by 500 IU three times per week for 3 additional weeks. Typically combined with SERMs (clomiphene, tamoxifen) to restore pituitary feedback.
Reconstitution and Dose Calculation
Standard 5000 IU vial reconstituted with 1.0 mL bacteriostatic water:
Resulting concentration: 5000 IU/mL
| Desired Dose | Volume on U-100 Syringe |
|---|---|
| 250 IU | 5 units (0.05 mL) |
| 500 IU | 10 units (0.10 mL) |
| 1000 IU | 20 units (0.20 mL) |
| 2000 IU | 40 units (0.40 mL) |
SC injection in the abdominal fold or thigh is the most common route in research contexts.
Storage
HCG is a glycoprotein with two non-covalently linked subunits (alpha and beta). Its stability depends critically on temperature:
- Unreconstituted lyophilized powder: Store between 2-8°C. DO NOT freeze at -20°C — this can dissociate the subunits and reduce biological activity.
- After reconstitution: Store between 2-8°C for up to 30 days. Protect from direct light. Do not shake.
- Room temperature: Avoid prolonged exposure. A vial left at room temperature for more than a few hours loses biological activity cumulatively.
Documented Adverse Effects
- Gynecomastia: HCG stimulates testicular testosterone production, which can aromatize to estradiol. In sensitive individuals or without a concomitant aromatase inhibitor, this may induce breast tissue development.
- Acne: A consequence of the increase in androgens.
- Water retention: Secondary effect of elevated estradiol.
- Prolonged pituitary suppression: Chronic high-dose HCG use may desensitize LHCGR receptors and, paradoxically, reduce the testis’s long-term capacity to respond to endogenous LH.
- Local injection site reactions: Erythema or induration at the injection site, generally mild and transient.
Regulatory Framework
Approved HCG products (Pregnyl, Novarel, Ovidrel) require a medical prescription in most countries. Indications include prepubertal cryptorchidism, male hypogonadotropic hypogonadism, ovulation induction in women, and as an ovulatory trigger in assisted reproduction treatments. Research vials are not the approved pharmaceutical product and are not subject to the same quality controls.
This content is for educational purposes only. Not medical advice. Always consult a healthcare professional before starting any research protocol.
Reported protocol (research reference)
| Vial sizes | 5000 mg |
|---|---|
| Reported dose | TRT support: 500 IU × 2/week SC. Male fertility: 1000-2000 IU × 3/week SC. PCT: 500-1000 IU/day × 10 days, then 500 IU × 3/week × 3 weeks. At 5000 IU/mL: 500 IU = 10 units (0.10 mL) on a U-100 syringe. |
| Half-life | 24-36 hours via SC. |
| FDA status | FDA approved |